The global Wound Biologics market is anticipated to increase at a 7.6% CAGR to reach value US$ 533.8 Mn in 2030
.jpg
"The Global Electric Paint Market 2020-2030 (USD Million)")
The global wound biologics market was valued at USD 1,464.7 million in 2019. Increase in prevalence of chronic wounds, rapidly growing geriatric population and high cases of burns and traumatic injuries across the globe are major factors driving the global wound biologics market.
Growing adoption of sedentary lifestyle, unhealthy food habits, aggravating chronic diseases such as obesity and diabetes are major factors for the formation of chronic wounds. Chronic wounds including diabetic foot ulcers, pressure ulcers, and venous leg ulcers are difficult and expensive to heal posing huge cost burden on the healthcare systems. Thus, the need for rapid wound-healing has significantly increased owing to the increasing number of patients suffering from diabetes and obesity. According to International Diabetes Federation (IDF), 463 million people were living with diabetes globally in 2019 and this number is expected to reach 700 million by 2045. These factors are anticipated to fuel the demand for wound biologics over the forecast timeframe.
Moreover, surging geriatric population susceptible to chronic diseases along with rapid rise in traumatic injuries and burn cases across the globe are expected to drive the demand for wound biologics in the future. However, high cost of wound care biologics and higher rejection rate associated with skin grafts & substitutes is expected to hinder the growth of the market over the forecast period.
The global wound biologics market is categorized based on product, wound type, end-users, and region. On the basis of product, biological skin substitutes segment held the largest share of the global wound biologics market in 2019 owing to its wide adoption for healing burn wounds. By wound type, ulcers segment is anticipated to grow at a lucrative rate over the forecast period. Geographically, North America dominated the global wound biologics market in 2019, however, Asia Pacific is expected to be the fastest growing region by 2028.
Key players operating in the global wound biologics market include Mölnlycke Health Care AB, Mimedx Group, Smith & Nephew plc, Wright Medical, Anika Therapeutics, Derma Sciences Inc. (Integra LifeSciences Corporation), Solsys Medical, Organogenesis, Kerecis, and Vericel Corporation among others.
Wound Biologics Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2030 |
| Study Period | 2018-2030 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2030 | US$ 533.8 Million |
| Growth Rate | CAGR of 7.6% during 2020-2030 |
| Segment Covered | Product, Wound Type, End-users, Regions |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | Smith & Nephew plc, Mölnlycke Health Care AB, Mimedx Group, Wright Medical, Anika Therapeutics, Derma Sciences Inc. (Integra LifeSciences Corporation), Solsys Medical, Organogenesis, Kerecis, and Vericel Corporation among others. |
Key Segments of the Global Wound Biologics Market
Product Overview, (USD Million)
- Biological Skin Substitutes
- Allograft
- Xenograft
- Biosynthetic Products
- Topical Agents
Wound Type Overview, (USD Million)
- Ulcers
- Diabetic Foot Ulcers
- Venous Leg Ulcers
- Pressure Ulcers
- Others
- Surgical and Traumatic Wounds
- Burns
End-users Overview, (USD Million)
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Others
Regional Overview, (USD Million)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC countries
- South Africa
- Rest of Middle East & Africa
Reasons for the study
- Increase in burn cases and traumatic injuries across the globe
- Rising geriatric population worldwide
- Increase in incidence of chronic disorders such as diabetes and obesity
What does the report include?
- The study on the global wound biologics market includes qualitative insights such as drivers, restraints, challenges and opportunities
- Additionally, the market has been evaluated using the Porter’s Five Forces analysis
- The study covers qualitative and quantitative analysis of the market segmented on the basis of product, wound type, and end-users. Moreover, the study on wound biologics market provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players operating in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global wound biologics market is suitable for all the players across the value chain including raw material suppliers, hospitals, clinics, ambulatory surgical centers, medical device manufacturers, healthcare organizations, distributors, suppliers and technology geeks
- Venture capitalists and investors looking for more information on the future outlook of the global wound biologics market
- Consultants, analysts, researchers, and academicians looking for insights shaping the global wound biologics market
Frequently Asked Questions (FAQ) :
The major contenders in the global market Smith & Nephew plc, Mölnlycke Health Care AB, Mimedx Group, Wright Medical, Anika Therapeutics, Derma Sciences Inc. (Integra LifeSciences Corporation), Solsys Medical, Organogenesis, Kerecis, and Vericel Corporation among others.
The wound biologics market is growing at a CAGR of 7.6 % over the forecast period.
North America dominated the market for wound biologics market and accounted for the largest revenue share.
The current trend for burn wound treatment has moved to a more holistic approach to long-term type and function of healed burn wounds, as well as improved quality of life. As a result, numerous skin substitutes have emerged in the treatment of acute burn injury as well as post-burn reconstructions. Skin substitutes play a significant role in the treatment of multiple etiologies of deep dermal and full thickness wounds. Diabetic foot ulcers, venous leg ulcers, and pressure ulcers are among the most common chronic wounds. With a global incidence rate of 6.3 percent, diabetic foot ulcers are one of the most common complications associated with diabetes. Diabetes is becoming more common, which increases the risk of chronic wounds. As a result, the market for wound biologics will rise in the future as the number of chronic wounds rises. The skin substitutes offer various advantages such as it provides a rapid wound coverage solution that may require a less vascularized wound bed, an improvement in the dermal portion of the healed wound, the reduction or removal of wound healing inhibitory factors, a decreased inflammatory reaction, and associated scarring.
The global wound biologics market has been segmented based on product, wound type, end-users, and region. Based on product, the wound biologics market is segmented into biological skin substitutes, and topical agents. Biological skin substitutes are further categorized into allograft, xenograft, and biosynthetic products. Biological skin substitutes segment held substantial share of the global market in 2019. Biological skin substitutes are majorly used for the treatment of acute burn wounds. The biological skin substitutes allow for the formation of a more natural new dermis with excellent re-epithelialization properties. These have the ability to improve healing rate and mitigate risks in a variety of other skin wounds, including burn injuries, pressure, ischemia, trauma, surgery, and skin diseases, among others. All such factors will positively influence the growth of the segment in the coming years.
On the basis on wound type, the global wound biologics market is categorized into ulcers, surgical and traumatic wounds, and burns. Ulcers are further sub-categorized into diabetic foot ulcers, venous leg ulcers, pressure ulcers, and others. Ulcers grabbed majority of the market share in 2019 owing to surge in chronic diseases such as diabetes and obesity leading to formation of diabetic foot ulcers and pressure ulcers. For instance, it is estimated that the risk of developing a foot ulcer in a diabetic patient is expected to be between 19 and 34 percent over their lifetime. More than half of diabetic foot ulcers become infected, with amputation occurring in 20% of cases.
Based on end-users, wound biologics market is segmented into hospitals and clinics, ambulatory surgical centers and others. Hospitals & clinics dominated the global wound biologics market in 2019.
The global wound biologics market is cumulative to North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global wound biologics market in 2019, however Asia Pacific is expected to grow at a highest pace through 2028.
High cost burden of chronic wounds along with increase in incidence of diabetes and obesity in the U.S. are major factors expected to drive the wound biologics market in the region. According to the International Diabetes Federation (IDF), nearly 48 million people in North America had diabetes in 2019, with that number predicted to grow to 63 million by 2045, representing a 33 percent increase. Moreover, the cost of chronic wounds in the U.S. is estimated at USD 25 billion per year. Furthermore, wide availability of wound biologics is other major factor likely to boost the growth of the market in North America.
However, Asia Pacific is expected to grow at a rapid pace over the next few years. There is a strong growth potential in the emerging economies such as India, and China. The rapidly rising geriatric population in countries such as India and China provide large market for wound biologics. According to the United Nations, China and India together were home to over one third of the world’s population aged 60 years or over in 2017. Furthermore, rise in burn injuries and accidents will fuel the need for wound biologics over the coming years